|
ES2357057T3
(es)
|
2002-04-30 |
2011-04-15 |
Kudos Pharmaceuticals Limited |
Derivados de ftalazinona.
|
|
US7449464B2
(en)
|
2003-03-12 |
2008-11-11 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
GB0305681D0
(en)
|
2003-03-12 |
2003-04-16 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
|
KR101146806B1
(ko)
*
|
2003-03-12 |
2012-05-22 |
메이브릿지 리미티드 |
프탈라지논 유도체
|
|
GB0317466D0
(en)
*
|
2003-07-25 |
2003-08-27 |
Univ Sheffield |
Use
|
|
BRPI0412348A
(pt)
|
2003-07-30 |
2006-09-05 |
Xenon Pharmaceuticals Inc |
derivados de piperazina e seu uso como agentes terapêuticos
|
|
NZ545747A
(en)
|
2003-08-06 |
2010-06-25 |
Senomyx Inc |
T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
|
|
GB0324159D0
(en)
|
2003-10-15 |
2003-11-19 |
Glaxo Group Ltd |
Novel compounds
|
|
PT2305221E
(pt)
*
|
2003-12-01 |
2015-09-03 |
Cancer Res Inst |
Inibidores de reparação de danos no adn para tratamento de cancro
|
|
GB0419072D0
(en)
|
2004-08-26 |
2004-09-29 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
|
NZ553979A
(en)
*
|
2004-08-26 |
2009-05-31 |
Kudos Pharm Ltd |
4-heteroarylmethyl substituted phthalazinone derivatives
|
|
EP1645556A1
(en)
*
|
2004-10-07 |
2006-04-12 |
Boehringer Ingelheim International GmbH |
Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents
|
|
CA2597134C
(en)
|
2005-02-04 |
2015-05-26 |
Senomyx, Inc. |
Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
|
|
GB0510142D0
(en)
*
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds A1
|
|
TW200715993A
(en)
|
2005-06-15 |
2007-05-01 |
Senomyx Inc |
Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
|
|
ATE455117T1
(de)
*
|
2005-09-23 |
2010-01-15 |
Equispharm Co Ltd |
5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren
|
|
GB0521373D0
(en)
|
2005-10-20 |
2005-11-30 |
Kudos Pharm Ltd |
Pthalazinone derivatives
|
|
EP2010009B1
(en)
|
2006-04-21 |
2017-06-14 |
Senomyx, Inc. |
Processes for preparing solid flavorant compositions
|
|
GB0610680D0
(en)
*
|
2006-05-31 |
2006-07-12 |
Istituto Di Ricerche D Biolog |
Therapeutic compounds
|
|
AU2007266840B2
(en)
*
|
2006-05-31 |
2012-09-20 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)
|
|
US20090281086A1
(en)
*
|
2006-06-15 |
2009-11-12 |
Kudos Pharmaceuticals Limited |
2 -oxyheteroarylamide derivatives as parp inhibitors
|
|
WO2008020180A2
(en)
*
|
2006-08-17 |
2008-02-21 |
Kudos Pharmaceuticals Limited |
Methods of increasing the sensitivity of cancer cells to dna damage
|
|
AU2013201880B2
(en)
*
|
2006-10-17 |
2015-06-25 |
Kudos Pharmaceuticals Limited |
Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
|
|
UY30639A1
(es)
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
|
PE20081229A1
(es)
*
|
2006-12-01 |
2008-08-28 |
Merck & Co Inc |
Antagonistas de receptor de orexina de diazepam sustituido
|
|
SI2698062T1
(sl)
|
2006-12-28 |
2015-12-31 |
Abbvie Inc. |
Inhibitorji poli (ADP-riboza) polimeraze
|
|
RU2009147819A
(ru)
*
|
2007-05-25 |
2011-06-27 |
Астразенека Аб (Se) |
Комбинация ингибиторов снк и parp для лечения злокачественных новообразований
|
|
CA2687931C
(en)
|
2007-05-31 |
2016-05-24 |
Boehringer Ingelheim International Gmbh |
Ccr2 receptor antagonists and uses thereof
|
|
US20090023727A1
(en)
*
|
2007-07-05 |
2009-01-22 |
Muhammad Hashim Javaid |
Phthalazinone derivatives
|
|
GB0716532D0
(en)
|
2007-08-24 |
2007-10-03 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
DK2209375T3
(da)
|
2007-10-03 |
2014-10-06 |
Eisai Inc |
Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
|
|
EP2212296B1
(en)
*
|
2007-10-17 |
2014-12-03 |
Kudos Pharmaceuticals Limited |
4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl]-2h-phthalaz in-1-one
|
|
ES2524787T3
(es)
|
2007-11-15 |
2014-12-12 |
Msd Italia S.R.L. |
Derivados de piridazinona como inhibidores de PARP
|
|
CL2008003553A1
(es)
*
|
2007-12-05 |
2009-11-27 |
Grindeks Jsc |
Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
|
|
AU2008335135A1
(en)
*
|
2007-12-11 |
2009-06-18 |
Cytopathfinder, Inc. |
Carboxamide compounds and their use as chemokine receptor agonists
|
|
UY31603A1
(es)
*
|
2008-01-23 |
2009-08-31 |
|
Derivados de ftalazinona
|
|
SG193842A1
(en)
|
2008-08-06 |
2013-10-30 |
Biomarin Pharm Inc |
Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
|
|
MY160340A
(en)
*
|
2008-10-07 |
2017-02-28 |
Astrazeneca Uk Ltd |
Pharmaceutical formulation 514
|
|
EA020548B1
(ru)
|
2008-12-19 |
2014-12-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
|
|
TW201114756A
(en)
*
|
2009-07-15 |
2011-05-01 |
Astrazeneca Ab |
Phthalazinone compound
|
|
WO2011030139A1
(en)
|
2009-09-11 |
2011-03-17 |
Astrazeneca Ab |
4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
|
|
EP2322658A1
(en)
|
2009-11-13 |
2011-05-18 |
Centre National de la Recherche Scientifique (CNRS) |
Signature for the diagnosis of breast cancer aggressiveness and genetic instability
|
|
WO2011058367A2
(en)
|
2009-11-13 |
2011-05-19 |
Astrazeneca Ab |
Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
|
|
ME01908B
(me)
|
2009-12-17 |
2014-12-20 |
Boehringer Ingelheim Int |
Novi antagonisti ccr2 receptora i njihova primjena
|
|
US8541403B2
(en)
*
|
2010-02-03 |
2013-09-24 |
Biomarin Pharmaceutical Inc. |
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
|
|
PT2533640T
(pt)
|
2010-02-08 |
2017-01-03 |
Medivation Technologies Inc |
Processos de síntese de derivados de di-hidropiridoftalazinona
|
|
US8877745B2
(en)
|
2010-05-12 |
2014-11-04 |
Boehringer Ingelheim International Gmbh |
CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
|
WO2011141477A1
(en)
|
2010-05-12 |
2011-11-17 |
Boehringer Ingelheim International Gmbh |
New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
|
US8841313B2
(en)
|
2010-05-17 |
2014-09-23 |
Boehringer Ingelheim International Gmbh |
CCR2 antagonists and uses thereof
|
|
WO2011147772A1
(en)
|
2010-05-25 |
2011-12-01 |
Boehringer Ingelheim International Gmbh |
Ccr2 receptor antagonists
|
|
EP2576538B1
(en)
|
2010-06-01 |
2015-10-28 |
Boehringer Ingelheim International GmbH |
New CCR2 antagonists
|
|
EP2598491B1
(en)
*
|
2010-07-27 |
2015-09-02 |
Cadila Healthcare Limited |
Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
|
|
CN102372716A
(zh)
|
2010-08-09 |
2012-03-14 |
江苏恒瑞医药股份有限公司 |
酞嗪酮类衍生物、其制备方法及其在医药上的应用
|
|
BR112013009117A2
(pt)
|
2010-10-21 |
2016-07-19 |
Biomarin Pharm Inc |
sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo.
|
|
ES2590682T3
(es)
|
2010-12-02 |
2016-11-23 |
Shanghai De Novo Pharmatech Co Ltd. |
Derivados heterocíclicos, procesos de preparación y usos médicos de los mismos
|
|
CA2829123C
(en)
*
|
2011-03-14 |
2016-04-12 |
Eternity Bioscience Inc. |
Quinazolinediones and their use
|
|
EP2709618A4
(en)
*
|
2011-05-10 |
2014-11-05 |
UNIVERSITé LAVAL |
METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION
|
|
CA2835339A1
(en)
|
2011-05-18 |
2012-11-22 |
Centre National De La Recherche Scientifique (Cnrs) |
Signature for the diagnosis of cancer aggressiveness and genetic instability
|
|
TWI577693B
(zh)
*
|
2011-05-31 |
2017-04-11 |
江蘇康緣藥業股份有限公司 |
聚（ａｄｐ-核糖）聚合酶之三環抑制劑
|
|
EP2731941B1
(en)
|
2011-07-15 |
2019-05-08 |
Boehringer Ingelheim International GmbH |
Novel and selective ccr2 antagonists
|
|
EP2734199B1
(en)
|
2011-07-22 |
2022-11-16 |
Pacylex Pharmaceuticals Inc. |
Synthetic lethality and the treatment of cancer
|
|
CN103130723B
(zh)
|
2011-11-30 |
2015-01-14 |
成都地奥制药集团有限公司 |
一种多聚(adp-核糖)聚合酶抑制剂
|
|
US9790556B2
(en)
|
2012-01-05 |
2017-10-17 |
Centre National De La Recherche Scientifique (Cnrs) |
Signature for the diagnosis of lung cancer aggressiveness and genetic instability
|
|
CN102964354B
(zh)
*
|
2012-11-16 |
2014-08-13 |
江苏先声药业有限公司 |
一类噻吩并咪唑衍生物及其应用
|
|
CA2890309A1
(en)
|
2012-12-31 |
2014-07-03 |
Cadila Healthcare Limited |
Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
|
|
WO2014160440A1
(en)
|
2013-03-13 |
2014-10-02 |
Flatley Discovery Lab |
Pyridazinone compounds and methods for the treatment of cystic fibrosis
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
MX364438B
(es)
*
|
2013-03-15 |
2019-04-26 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
JP6423875B2
(ja)
*
|
2013-07-31 |
2018-11-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
オキソキナゾリニル−ブタンアミド誘導体
|
|
AU2014304953B2
(en)
*
|
2013-08-07 |
2018-02-22 |
Merck Patent Gmbh |
Piperidine urea derivatives
|
|
KR101670126B1
(ko)
|
2013-09-13 |
2016-10-27 |
일동제약(주) |
신규 프탈라지논 유도체 및 그 제조방법
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
CN105985294B
(zh)
*
|
2015-02-11 |
2020-12-25 |
四川科伦药物研究院有限公司 |
一种奥拉帕尼的制备方法
|
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
CN106146492A
(zh)
*
|
2015-04-17 |
2016-11-23 |
上海汇伦生命科技有限公司 |
杂环并咪唑类化合物、其药物组合物及其制备方法和用途
|
|
CA2983927A1
(en)
|
2015-05-06 |
2016-11-10 |
The Regents Of The University Of California |
K-ras modulators
|
|
EP3298005B1
(en)
|
2015-05-21 |
2024-01-24 |
The Regents of The University of California |
Anti-cancer compounds
|
|
AU2016287584B2
(en)
|
2015-07-02 |
2020-03-26 |
Centrexion Therapeutics Corporation |
(4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
|
|
DK3325662T3
(da)
|
2015-07-17 |
2023-11-27 |
Pacylex Pharmaceuticals Inc |
Epigenetisk inaktivering af nmt2
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
EP3325623B3
(en)
|
2015-07-23 |
2021-01-20 |
Institut Curie |
Use of a combination of dbait molecule and parp inhibitors to treat cancer
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
CN106554316B
(zh)
*
|
2015-09-28 |
2019-03-08 |
上海医药集团股份有限公司 |
一种制备1-[5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酰基]哌嗪的方法
|
|
GB201519573D0
(en)
|
2015-11-05 |
2015-12-23 |
King S College London |
Combination
|
|
CA3005089A1
(en)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
|
CN119185322A
(zh)
*
|
2015-11-20 |
2024-12-27 |
生华生物科技股份有限公司 |
用于治疗癌症的四环喹诺酮类似物组合疗法
|
|
CZ201682A3
(cs)
|
2016-02-15 |
2017-08-23 |
Zentiva, K.S. |
Solvatované krystalické formy olaparibu, jejich příprava a použití
|
|
WO2017191562A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Alembic Pharmaceuticals Limited |
Process for the preparation of olaparib and polymorphs thereof
|
|
IL263917B
(en)
|
2016-06-24 |
2022-07-01 |
Univ California |
Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
|
|
CZ2016391A3
(cs)
|
2016-06-29 |
2018-01-10 |
Zentiva, K.S. |
Farmaceutická formulace olaparibu
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
CN109563080B
(zh)
|
2016-08-24 |
2021-07-30 |
台湾神隆股份有限公司 |
奥拉帕尼的制备方法
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
|
CN107955001A
(zh)
|
2016-10-14 |
2018-04-24 |
上海汇伦生命科技有限公司 |
抗肿瘤杂环并咪唑类化合物的药用盐
|
|
WO2018122168A1
(en)
|
2016-12-29 |
2018-07-05 |
Bayer Pharma Aktiengesellschaft |
Combinations of bub1 kinase and parp inhibitors
|
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
WO2018162439A1
(en)
|
2017-03-08 |
2018-09-13 |
Onxeo |
New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
|
|
SG11201909570PA
(en)
|
2017-04-20 |
2019-11-28 |
Univ California |
K-ras modulators
|
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
JP2020521740A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
|
|
CA3031777A1
(en)
|
2018-01-31 |
2019-07-31 |
Apotex Inc. |
Crystalline form of olaparib
|
|
AU2019227294B2
(en)
|
2018-02-15 |
2023-06-15 |
Senhwa Biosciences, Inc. |
Quinolone analogs and their salts, compositions, and method for their use
|
|
US11542282B2
(en)
*
|
2018-02-28 |
2023-01-03 |
The Trustees Of The University Of Pennsylvania |
Low affinity poly(AD-ribose) polymerase 1 dependent cytotoxic agents
|
|
WO2019175132A1
(en)
|
2018-03-13 |
2019-09-19 |
Onxeo |
A dbait molecule against acquired resistance in the treatment of cancer
|
|
GB201804924D0
(en)
*
|
2018-03-27 |
2018-05-09 |
Univ Oxford Innovation Ltd |
Radiolabelled compound
|
|
WO2019196812A1
(zh)
*
|
2018-04-09 |
2019-10-17 |
上海科技大学 |
蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
|
|
MX2020012066A
(es)
|
2018-05-14 |
2021-04-28 |
Nuvation Bio Inc |
Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
|
|
CN108558773A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种奥拉帕尼药物中间体的制备方法
|
|
BR112021001709A2
(pt)
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
|
MX2021013774A
(es)
|
2019-05-14 |
2021-12-10 |
Nuvation Bio Inc |
Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
|
|
BR112022000534A2
(pt)
|
2019-07-19 |
2022-05-10 |
Astrazeneca Ab |
Inibidores de parp1
|
|
TW202131930A
(zh)
|
2019-11-13 |
2021-09-01 |
美商諾維雪碧歐公司 |
抗癌核荷爾蒙受體標靶化合物
|
|
US20230049029A1
(en)
*
|
2020-01-07 |
2023-02-16 |
Shanghai Huayu Biotechnology Co. Lts |
Combination cancer therapy using chk inhibitor
|
|
CN115038447A
(zh)
|
2020-01-09 |
2022-09-09 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症的组合疗法
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
US20240016775A1
(en)
*
|
2020-02-24 |
2024-01-18 |
Fukang (Shanghai) Health Technology Co., Ltd |
Anti-coronavirus application of poly adp ribose polymerase inhibitor
|
|
US12060345B2
(en)
|
2020-04-21 |
2024-08-13 |
Idience Co., Ltd. |
Process for preparing a phthalazinone derivative and intermediates thereof
|
|
BR112022021321A2
(pt)
|
2020-04-21 |
2022-12-20 |
Idience Co Ltd |
Formas cristalinas do composto de ftalazinona.
|
|
PL4143182T3
(pl)
|
2020-04-28 |
2025-03-31 |
Rhizen Pharmaceuticals Ag |
Nowe związki użyteczne jako inhibitory polimerazy poli(adprybozy) (parp)
|
|
CN111592522B
(zh)
*
|
2020-06-17 |
2022-09-09 |
郑州大学 |
一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途
|
|
US11795158B2
(en)
|
2020-06-25 |
2023-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
JP7453475B2
(ja)
|
2020-09-16 |
2024-03-19 |
ナフォーミックス テクノロジーズ リミテッド |
オラパリブシュウ酸共結晶及びその医薬的使用
|
|
EP4225314A1
(en)
|
2020-10-09 |
2023-08-16 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
|
US12059419B2
(en)
|
2020-10-16 |
2024-08-13 |
Idience Co., Ltd. |
Pharmaceutical composition comprising phthalazinone derivatives
|
|
WO2022090938A1
(en)
|
2020-10-31 |
2022-05-05 |
Rhizen Pharmaceuticals Ag |
Phthalazinone derivatives useful as parp inhibitors
|
|
CN112500379B
(zh)
*
|
2020-12-23 |
2024-01-23 |
南京方生和医药科技有限公司 |
一种奥拉帕利中间体及奥拉帕利的制备方法
|
|
IL306010A
(en)
|
2021-03-23 |
2023-11-01 |
Nuvation Bio Inc |
Anticancer compounds against the nuclear hormone receptor
|
|
CN113024516B
(zh)
*
|
2021-03-29 |
2022-05-17 |
中国药科大学 |
双靶点parp/ezh2抑制剂、制备方法及用途
|
|
CA3214298A1
(en)
|
2021-04-08 |
2022-10-13 |
Swaroop Kumar Venkata Satya VAKKALANKA |
Inhibitors of poly(adp-ribose) polymerase
|
|
AU2022269568A1
(en)
|
2021-05-03 |
2023-11-16 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
AU2022276986B2
(en)
|
2021-05-18 |
2025-07-03 |
Onconic Therapeutics Inc. |
Parp inhibitor-resistant cancer therapeutic agent
|
|
KR20240016344A
(ko)
|
2021-06-02 |
2024-02-06 |
아스트라제네카 아베 |
유방암의 치료 방법
|
|
WO2023017393A1
(en)
|
2021-08-09 |
2023-02-16 |
Glenmark Life Sciences Limited |
Process for the preparation of olaparib, and crystalline form thereof
|
|
KR102645122B1
(ko)
|
2021-08-25 |
2024-03-07 |
주식회사 보령 |
올라파립의 제조방법
|
|
CN120309514A
(zh)
*
|
2021-09-15 |
2025-07-15 |
上海博邦医药科技有限公司 |
一种奥拉帕尼中间体的制备方法
|
|
WO2023084311A1
(en)
|
2021-11-10 |
2023-05-19 |
Nuformix Technologies Limited |
Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical use
|
|
WO2023089527A1
(en)
|
2021-11-18 |
2023-05-25 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
|
AU2022422276B2
(en)
|
2021-12-21 |
2025-12-11 |
Astrazeneca Ab |
Methods of treating brain tumours and neuroblastomas
|
|
KR102776660B1
(ko)
*
|
2022-01-25 |
2025-03-04 |
재단법인 한국파스퇴르연구소 |
벤조다이옥세인 유도체 화합물 및 이의 의약 용도
|
|
IL314798A
(en)
|
2022-02-15 |
2024-10-01 |
Astrazeneca Ab |
Prostate cancer treatment methods
|
|
WO2024199668A1
(en)
|
2023-03-31 |
2024-10-03 |
Astrazeneca Ab |
Dosing regiment of azd5305
|
|
CN119055777A
(zh)
|
2023-05-31 |
2024-12-03 |
阿斯利康(瑞典)有限公司 |
用于治疗卵巢癌的方法、组合物和组合
|
|
WO2024261243A1
(en)
|
2023-06-21 |
2024-12-26 |
Hemispherian As |
Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
|
|
CN119488588A
(zh)
|
2023-08-17 |
2025-02-21 |
阿斯利康(瑞典)有限公司 |
用于治疗子宫内膜癌的方法、组合物和组合
|
|
WO2025120513A1
(en)
|
2023-12-05 |
2025-06-12 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
|
|
WO2025153668A1
(en)
|
2024-01-19 |
2025-07-24 |
Astrazeneca Ab |
Pharmaceutical compositions comprising azd5305
|